<?xml version='1.0' encoding='utf-8'?>
<document id="28374622"><sentence text="Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes."><entity charOffset="35-46" id="DDI-PubMed.28374622.s1.e0" text="saxagliptin" /><entity charOffset="52-65" id="DDI-PubMed.28374622.s1.e1" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.28374622.s1.e0" e2="DDI-PubMed.28374622.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28374622.s1.e0" e2="DDI-PubMed.28374622.s1.e1" /></sentence><sentence text="Combining a dipeptidyl peptidase-4 inhibitor and a sodium-glucose cotransporter type 2 inhibitor is an attractive option to treat hyperglycaemia in type 2 diabetes" /><sentence text=" Areas covered: The saxagliptin plus dapagliflozin combination is carefully analysed, focusing on: 1) pharmacokinetic properties, 2) pharmacodynamics data, and 3) results of randomised controlled trials (dual combination versus either monotherapy, sequential therapy saxagliptin added to dapagliflozin or dapagliflozin added to saxagliptin)"><entity charOffset="20-31" id="DDI-PubMed.28374622.s3.e0" text="saxagliptin" /><entity charOffset="37-50" id="DDI-PubMed.28374622.s3.e1" text="dapagliflozin" /><entity charOffset="267-278" id="DDI-PubMed.28374622.s3.e2" text="saxagliptin" /><entity charOffset="288-301" id="DDI-PubMed.28374622.s3.e3" text="dapagliflozin" /><entity charOffset="305-318" id="DDI-PubMed.28374622.s3.e4" text="dapagliflozin" /><entity charOffset="328-339" id="DDI-PubMed.28374622.s3.e5" text="saxagliptin" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e0" e2="DDI-PubMed.28374622.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e0" e2="DDI-PubMed.28374622.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e0" e2="DDI-PubMed.28374622.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e0" e2="DDI-PubMed.28374622.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e0" e2="DDI-PubMed.28374622.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e0" e2="DDI-PubMed.28374622.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e1" e2="DDI-PubMed.28374622.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e1" e2="DDI-PubMed.28374622.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e1" e2="DDI-PubMed.28374622.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e1" e2="DDI-PubMed.28374622.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e1" e2="DDI-PubMed.28374622.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e2" e2="DDI-PubMed.28374622.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e2" e2="DDI-PubMed.28374622.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e2" e2="DDI-PubMed.28374622.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e2" e2="DDI-PubMed.28374622.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e3" e2="DDI-PubMed.28374622.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e3" e2="DDI-PubMed.28374622.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e3" e2="DDI-PubMed.28374622.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e4" e2="DDI-PubMed.28374622.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28374622.s3.e4" e2="DDI-PubMed.28374622.s3.e5" /></sentence><sentence text=" Expert opinion: Pharmacokinetic findings demonstrate the absence of drug-drug interaction and the bioequivalence of the FDC compared with separated tablets" /><sentence text=" Pharmacodynamic observations confirm a complementary mode of action of the two agents" /><sentence text=" Dual saxagliptin-dapagliflozin therapy is more potent than either monotherapy"><entity charOffset="6-17" id="DDI-PubMed.28374622.s6.e0" text="saxagliptin" /><entity charOffset="18-31" id="DDI-PubMed.28374622.s6.e1" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.28374622.s6.e0" e2="DDI-PubMed.28374622.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28374622.s6.e0" e2="DDI-PubMed.28374622.s6.e1" /></sentence><sentence text=" It may be used as an initial combination, although this approach remains debatable and should probably be reserved in case of high glycated hemoglobin, or a stepwise strategy, according to a personalized approach" /><sentence text=" The developed saxagliptin-dapagliflozin FDC may simplify anti-hyperglycemic therapy and improve drug compliance"><entity charOffset="15-26" id="DDI-PubMed.28374622.s8.e0" text="saxagliptin" /></sentence><sentence text="" /></document>